Vertex to present 11 abstracts from CF R&D program at NACFC
Vertex Pharmaceuticals announced that 11 abstracts from its cystic fibrosis research and development program will be presented at the annual North American Cystic Fibrosis Conference in Indianapolis, November 2 to 4, 2017. Previously announced data from the Phase 3 EVOLVE and EXPAND studies of the investigational tezacaftor/ivacaftor combination in people with CF ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance regulator gene will be presented for the first time. Additionally, data from the Phase 3 extension study of ORKAMBI in children with CF ages 6 to 11 who have two copies of the F508del mutation and real-world KALYDECO data will be presented. The company also submitted an abstract for the late-breaking poster session with previously announced Phase 1 and Phase 2 data for three different next-generation correctors -- VX-440, VX-152 and VX-659 -- in triple combination regimens with tezacaftor and ivacaftor in people with CF who have one F508del mutation and one minimal function mutation and in people with two copies of the F508del mutation. Collectively, the data at the Conference demonstrate continued progress across the company's CF program goals of providing enhanced treatment options for more people, demonstrating the disease-modifying effects of CFTR modulators, and expanding CFTR treatment options to all people with CF through the development of new medicines.